Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Payoneer Global Inc (PAYO) Price & Performance

BridgeBio Pharma IncTrade
Payoneer Global IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Payoneer Global Inc — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Payoneer Global Inc trades at $7.08 (market cap $2.40B). The key difference: BridgeBio Pharma Inc is far larger — about 6.8× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.

BBIOPAYO
Market Cap
$16.36B$2.40B
Sector
HealthTechnology
52-Week High
$90.17$7.17
52-Week Low
$47.29$4.27
Enterprise Value
$18.14B$2.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Payoneer Global Inc

Payoneer Global Inc. (PAYO) trades at $7.09, down 0.14% on the day, near its 52-week high of $7.67. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal mixed earnings with Q2 2026 EPS missing estimates at $0.02 versus $0.06 expected. Revenue growth remains solid, up 10% year-over-year excluding interest in Q2 2026. Sentiment is influenced by the pending acquisition by Nuvei for $7.40 per share, announced on June 15, 2026, which has sparked legal inquiries over fairness.

The outlook is cautiously optimistic with a consensus price target of $8.20 offering 16% upside, but risks include integration challenges from the Nuvei deal and earnings volatility. Investors should weigh the acquisition premium against potential shareholder litigation and execution risks in cross-border payment growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Payoneer Global Inc

Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.

Read more on PAYO